About Amylin Pharmaceuticals (NASDAQ:AMLN)
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:AMLN
CUSIPN/A
Phone+1-858-5522200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Amylin Pharmaceuticals (NASDAQ:AMLN) Frequently Asked Questions
What is Amylin Pharmaceuticals' stock symbol?
Amylin Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLN."
Has Amylin Pharmaceuticals been receiving favorable news coverage?
Press coverage about AMLN stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amylin Pharmaceuticals earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Amylin Pharmaceuticals?
Shares of AMLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Amylin Pharmaceuticals?
Amylin Pharmaceuticals' mailing address is 9360 Towne Centre Dr Ste 110, SAN DIEGO, CA 92121-3030, United States. The biopharmaceutical company can be reached via phone at +1-858-5522200.
MarketBeat Community Rating for Amylin Pharmaceuticals (AMLN)
MarketBeat's community ratings are surveys of what our community members think about Amylin Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amylin Pharmaceuticals (NASDAQ:AMLN) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/23/2016 forward)
Amylin Pharmaceuticals (NASDAQ:AMLN) Earnings History and Estimates Chart
Amylin Pharmaceuticals (NASDAQ AMLN) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/26/2012 | | ($0.27) | ($0.23) | | | View | N/A |  |
| 2/6/2012 | | ($0.16) | $0.09 | | | View | N/A | |
| 10/19/2011 | | ($0.13) | ($0.07) | | | View | N/A | |
| 7/26/2011 | | ($0.17) | ($0.21) | | | View | N/A | |
| 4/18/2011 | | ($0.23) | ($0.26) | | | View | N/A | |
| 1/26/2011 | | ($0.32) | ($0.13) | | | View | N/A | |
| 11/4/2010 | Q3 2010 | ($0.34) | ($0.31) | | | View | N/A | |
| 7/21/2010 | Q2 2010 | ($0.29) | ($0.28) | | | View | N/A | |
| 4/19/2010 | Q1 2010 | ($0.28) | ($0.27) | | | View | N/A | |
| 1/27/2010 | Q4 2009 | ($0.27) | ($0.32) | | | View | N/A | |
| 10/20/2009 | Q3 2009 | ($0.30) | ($0.19) | | | View | N/A | |
| 7/21/2009 | Q2 2009 | ($0.35) | ($0.36) | | | View | N/A | |
| 4/16/2009 | Q1 2009 | ($0.35) | ($0.34) | | | View | N/A | |
| 1/27/2009 | Q4 2008 | ($0.51) | ($0.36) | | | View | N/A | |
| 10/21/2008 | Q3 2008 | ($0.51) | ($0.46) | | | View | N/A | |
| 7/21/2008 | Q2 2008 | ($0.50) | ($0.47) | | | View | N/A | |
| 4/21/2008 | Q1 2008 | ($0.48) | ($0.51) | | | View | N/A | |
| 1/28/2008 | Q4 2007 | ($0.44) | ($0.57) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Amylin Pharmaceuticals (NASDAQ:AMLN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Amylin Pharmaceuticals (NASDAQ AMLN) Insider Trading and Institutional Ownership History
Amylin Pharmaceuticals (NASDAQ AMLN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Amylin Pharmaceuticals (NASDAQ AMLN) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Amylin Pharmaceuticals (NASDAQ:AMLN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amylin Pharmaceuticals (NASDAQ:AMLN) Income Statement, Balance Sheet and Cash Flow Statement
Amylin Pharmaceuticals (NASDAQ AMLN) Stock Chart for Monday, April, 23, 2018
Loading chart…
